logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5926.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5926.produseast1
Poster gallery (MSF Scientific Days International 2022) | Collections | MSF Science Portal
Poster gallery (MSF Scientific Days International 2022)

Poster gallery (MSF Scientific Days International 2022)

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (16)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (16)
  • CSV
  • BibTeX
  • EndNote

See more collections

New tools and approaches to drug-resistant TB

New tools and approaches to drug-resistant TB
The World Health Organization estimates that 410,000 people developed a drug-resistant tuberculosis infection (DR-TB) in 2022, only 40% of whom were diagnosed and started on treatment—and only 63% then cured. Given all these points of failure, innovation in preventing, diagnosing and treating DR-TB cannot come fast enough. To mark World TB Day (24 March 2024) the content collection linked below highlights recent work by MSF and collaborators to help change this grim picture. The TB-PRACTECAL and endTB studies delivered robust evidence for shorter, safer, more effective drug regimens that are already saving lives worldwide. Other studies explore new approaches to preventive treatment and simpler, quicker, accurate detection of TB and drug resistance—especially among difficult-to-diagnose populations such as children and people living with HIV. But to impact DR-TB globally these innovations must become widely accessible. This requires changes on many fronts, as described in an accompanying Collection (Expanding Access to Lifesaving New TB Tools).
Safe abortion care at MSF

Safe abortion care at MSF
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis

TB-PRACTECAL Trial—Evidence for a shorter, safer, more effect...
View All Collections

Unsafe abortion is a major cause of maternal death, and the only one that is completely preventable. Yet over 30 million unsafe abortions occur each year, leading to at least 29,000 deaths and millions of serious complications—nearly all in low- and middle-income countries. MSF teams see these tragic consequences first-hand, treating thousands of patients every year with severe, potentially life-threatening effects from unsafe abortion.


To mark International Safe Abortion Awareness Day (28 September 2024), this Collection presents highlights of MSF’s work on safe abortion care (SAC) as a way to reduce maternal death and injury. By re-assessing and reshaping how our projects deliver SAC in fragile and conflict-affected settings, we have been able to significantly expand services in those contexts and across MSF projects globally. In parallel, we also conducted in-depth studies of abortion complications and their contributing factors in fragile settings, where a dearth of evidence limits understanding of women's needs in accessing comprehensive care. These findings are helping to identify gaps in service delivery and inform operational decision-making.

Drug-resistant tuberculosis (DR-TB) remains an especially deadly form of the ancient scourge of TB, while current treatments are long, toxic, and ineffective for half of all patients. Aiming to change this unacceptable status quo, in the mid-2010’s MSF and partners launched three clinical trials to test novel regimens containing the first new TB drugs in decades. On 22 December 2022 the New England Journal of Medicine published findings from TB-PRACTECAL, a three-country randomized controlled trial, showing that a shorter regimen is safer and cured 89% of DR-TB patients, compared with 52% on the standard of care. These findings have already been incorporated into the World Health Organization’s new TB treatment guidelines. A separate study shows that the new regimen is also more cost-effective. Alongside these results the content collection linked below highlights other aspects of the trial, from community engagement strategies that helped shape TB-PRACTECAL to setbacks arising from the Covid-19 pandemic. It also examines urgent challenges in scaling up access to these life-saving drugs, including affordability and patent barriers.
Conference Material
|
Poster

What happened next? Analysing the impact of studies presented at MSF Scientific Days 2021

Jagadeesan S, Baker H
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Identifying critically ill children at risk of dying during hospital admission in Malawi: prognostic accuracy of a modified qSOFA score

Kumwenda M, Assies R, Snik I, Chathima G, Langton J,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Evaluation of mobile clinics by MSF in pastoralist community in Doolo Zone, Somali Region, Ethiopia: a mixed methods approach

Sahelie B, Ali Dubad B, Piening T, Chindong I, Osman M,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

What it takes to get it right: A qualitative study exploring optimal handover of health programmes in Tonkolili District, Sierra Leone

Sitali N, Briskin E, Foday J, Walker C, Keus K,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Kadamjay Area Biomonitoring (KAB) study, Kadamjay, Kyrgyzstan. A cross-sectional study

Aiylchiev S, Sharshenova A, Nascarella M, Sulaimanov E, Inagbe D,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Detection of Mycobacterium tuberculosis complex in the stool of pediatric patients using the Xpert MTB/Rif Ultra assay

Mun L, Gomez D, Sitali N, Rajabzoda A, Azamova S,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Evaluation of two HIV Differentiated Services Delivery Models (DSDM) implemented by MSF in Fishermen’s landing sites. Lakes George and Edward, Western Uganda. A mixed-methods study

Liu C, Josen K, Ayikoru H, Oucho N, Bazanye I,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Impact of Covid-19 on HIV care in Malawi and Uganda: mixed- methods study

Ben-Farhat J, Nesbitt RC, Bjertrup PJ, Mambula C, Balkan S,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Treatment outcomes of bedaquiline-exposed tuberculosis patients treated with a regimen containing bedaquiline and delamanid: findings from MSF clinic, Mumbai, India

Mongia H, Mansoor H, Mamnoon F, Silsarma A, Davuluri P,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Poster

Help-seeking behaviours, barriers, and enablers to accessing quality care after sexual and gender-based violence in MSF catchment areas in North Kivu, Democratic Republic of Congo

Reinholdz H, Nkweleko FF, Byenda J, Verputten M, Frielingsdorf H
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Specificity and sensitivity of Tetanos Quick Stick: prospective evaluation, Port-au-Prince, Haiti

Obach D, Fares K, Woolley SC, Jean-Louis C, Denis O,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Optimising the dosage of ready-to-use therapeutic food in children with uncomplicated kwashiorkor: a secondary analysis of the OptiMA-DRC trial

Cazes C, Sirna F, Phelan KPQ, Hubert V, Tshiala BK,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Management practices for pneumonia: a mixed-methods survey

Hinh J, Chan G, du Cros PAK, Walker SA, Graham SM,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Patient characteristics and TB treatment outcome of patients with Mono H resistance in M East ward, Mumbai, India

Mankar S, Vengurlekar D, Silsarma A, Sutar N, Oswal V,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Poster

The pathway to care for women experiencing severe abortion-related morbidity: qualitative results from the AMoCo study, Jigawa State, Nigeria

Moore AM, Fetters T, Williams TN, Pasquier E, Kantiok J,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Decentralization of insulin treatment through nurses and clinical officers in nine health centres in a rural county, Kenya: descriptive study

Borum Mølskov Bech M, Otieno Khisa A, Ndoca K, Ayuaya T, Kajuju P,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022